Patent search ap:("MODERNATX Page INC.") AND inv:"Tirtha CHAKRABORTY"

1.

发明公开
METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS 审中-公开

公开(公告)号：US20230338410A1

公开(公告)日：2023-10-26

申请号：US18167984

申请日：2023-02-13

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE , Tirtha CHAKRABORTY , Gilles BESIN , Ruchi JAIN

IPC: A61K31/7115 , C12N15/67 , A61K9/00 , A61K9/127 , C12N15/113

CPC classification number: A61K31/7115 , A61K9/0019 , A61K9/127 , C12N15/113 , C12N15/67 , C12N2310/141 , C12N2800/107 , C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

2.

发明申请
TERMINALLY MODIFIED RNA 审中-公开

公开(公告)号：US20190290742A1

公开(公告)日：2019-09-26

申请号：US16152945

申请日：2018-10-05

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY , Stephane BANCEL , Stephen G. HOGE , Atanu ROY , Antonin DE FOUGEROLLES , Noubar B. AFEYAN

IPC: A61K39/00 , C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

3.

发明申请
TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES 审中-公开

公开(公告)号：US20170362605A1

公开(公告)日：2017-12-21

申请号：US15533902

申请日：2015-12-18

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY

IPC: C12N15/85 , A61K48/00

CPC classification number: C12N15/85 , A61K48/00 , C12N2840/007

Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides comprising at least one terminal modification. Described herein are polynucleotides comprising at least one terminal modification, methods, processes, kits and devices using the polynucleotides comprising at least one terminal modification in one or more untranslate regions. Such untranslated regions may be a 5′ or 3′ untranslated region.

4.

发明申请
TERMINALLY MODIFIED RNA 有权

公开(公告)号：US20220395562A1

公开(公告)日：2022-12-15

申请号：US17127435

申请日：2020-12-18

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY , Stephane BANCEL , Stephen G. HOGE , Atanu ROY , Antonin DE FOUGEROLLES , Noubar B. AFEYAN

IPC: A61K39/00 , C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

5.

发明申请
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE 有权

公开(公告)号：US20210299278A1

公开(公告)日：2021-09-30

申请号：US17020522

申请日：2020-09-14

Applicant: ModernaTX, Inc.

Inventor： Stephane BANCEL , Tirtha CHAKRABORTY , Antonin DE FOUGEROLLES , Sayda M. ELBASHIR , Matthias JOHN , Atanu ROY , Susan WHORISKEY , Kristy M. WOOD , Paul HATALA , Jason P. SCHRUM , Kenechi EJEBE , Jeff Lynn ELLSWORTH , Justin GUILD

IPC: A61K48/00 , C12N15/85 , C07K14/47 , C07K14/62 , A61K31/7115 , C12N9/88 , A61K9/127 , C12N15/11 , C07K14/705 , C07K14/505 , C07K14/535 , C12N9/64 , C12N9/10 , C12N9/00 , C12N9/42 , C12N15/87 , C12P13/04 , A61K38/45 , C07K14/005 , C12N9/16 , C12N9/24 , C12N15/52 , A61K38/17 , C07K14/435 , C12P21/00 , C07K14/485 , C07H21/02 , C07K14/475 , C07K14/495 , C07K14/525 , C07K14/54 , C07K14/56 , C07K14/61 , C07K14/745 , C07K16/28 , C07K16/40 , C12N9/02 , C12N9/12 , C12N9/68 , A61K47/54 , A61K9/14 , A61K9/51 , A61K38/18 , A61K38/19 , A61K38/21 , A61K38/48 , C07K14/515 , C07K16/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

6.

发明申请
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS 审中-公开

公开(公告)号：US20170368200A1

公开(公告)日：2017-12-28

申请号：US15425645

申请日：2017-02-06

Applicant: ModernaTX, Inc.

Inventor： Stephane BANCEL , Tirtha CHAKRABORTY , Antonin DE FOUGEROLLES , Sayda M. ELBASHIR , Matthias JOHN , Atanu ROY , Susan WHORISKEY , Kristy M. WOOD , Paul HATALA , Jason P. SCHRUM , Kenechi EJEBE , Jeff Lynn ELLSWORTH , Justin GUILD

IPC: A61K48/00 , A61K9/127 , C12P21/00 , C12P13/04 , C12N15/87 , C12N15/85 , C12N15/52 , C12N15/11 , C12N9/00 , C12N9/88 , C12N9/64 , C12N9/42 , C12N9/24 , C12N9/16 , C12N9/10 , C07K16/00 , C07K14/705 , C07K14/62 , C07K14/56 , C07K14/535 , C07K14/525 , C07K14/515 , C07K14/505 , A61K47/54 , C07K14/47 , C07K14/435 , C07K14/005 , A61K38/48 , A61K38/45 , A61K38/21 , A61K38/19 , A61K38/18 , A61K38/17 , A61K31/7115 , A61K9/51 , A61K9/14 , C07K14/485 , A61K38/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

7.

发明申请
TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES 审中-公开

公开(公告)号：US20170202979A1

公开(公告)日：2017-07-20

申请号：US15326266

申请日：2015-07-17

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY , Stephen G. HOGE

IPC: A61K48/00 , A61K38/18 , C12N15/85 , C07K14/535 , C07K14/505 , C12N15/113 , A61K38/19 , C12N15/67

CPC classification number: A61K48/0066 , A61K38/1816 , A61K38/193 , C07H21/04 , C07K14/505 , C07K14/535 , C12N15/113 , C12N15/1136 , C12N15/67 , C12N15/85 , C12N2310/141 , C12N2310/3519 , C12N2840/102 , C12N2840/105

Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides comprising at least one terminal modification.